BBOT.US BridgeBio Oncology Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
2.14 USD
Close of Nov 14, 2026
1.98 14.87
Market cap
USD 172M
P/E
4.0x
P/B
0.65x
ROE
-60.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BBOT.US undervalued?

Graham number
Price2.14
Graham value6.27
Discount65.9%

BBOT.US trades 65.9% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BridgeBio Oncology Therapeutics, Inc. fundamental analysis

No fundamental analysis for BridgeBio Oncology Therapeutics, Inc. yet.

BridgeBio Oncology Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioav…

Full company profile